Pituitary Adenoma 2, Growth Hormone-Secreting

Watchlist

(log in to enable)

Retrieved

2019-09-22

Source

Omim

Trials

—

Genes

GH1, AIP, IGF1, GNAS, GPR101, SST, GHR, MEN1, PTPRF, GHRH, SSTR2, SSTR5, PRL, IGFBP3, AHR, PPARG, IGF1R, POU1F1, SOCS2, PRKAR1A, SLC20A1, CDKN1B, BRAF, REN, CST3, SSTR1, AGT, MTHFR, RET, SMS

GH1, AIP, IGF1, GNAS, GPR101, SST, GHR, MEN1, PTPRF, GHRH, SSTR2, SSTR5, PRL, IGFBP3, AHR, PPARG, IGF1R, POU1F1, SOCS2, PRKAR1A, SLC20A1, CDKN1B, BRAF, REN, CST3, SSTR1, AGT, MTHFR, RET, SMS, VDR, ARRB1, FGF21, GIPR, KL, TRIM21, GDNF, POMC, ESRP1, CALR, TP53, ACE, CDKN2A, TRH, TWIST1, TP73, TXN, SLPI, VEGFA, TNFSF11, TRHR, ZHX2, DGCR2, ABCB6, ZGLP1, MIR660, MIR21, ZACN, RSS, ARHGAP24, ASRGL1, EHMT1, FTO, MIB1, NDRG2, NPDC1, GPRC5C, GPRC5D, NAT10, UGT1A1, GHRL, SOST, PDLIM3, ATRNL1, RAB18, CCL2, CHEK2, UTS2, CCL27, CIB1, NAMPT, SLC5A2, GRK2, SRL, CYP11B2, GSTP1, GNAI2, GLP1R, GIP, GHRHR, GCG, FLNA, FGF2, E2F1, DPP4, DMBT1, CTSB, IGSF1, CRP, CISH, CALCA, CA1, BTF3P11, BAX, ATHS, APOE, AMH, ALPP, AGTR1, HSD11B1, INS, S100A1, OGG1, RORC, BRD2, RENBP, RAF1, PTPN4, PTPN3, PTH, AGRP, PRKACB, PLAGL1, TNFRSF11B, NRAS, EIF6, NPPB, NCAM1, MYC, MTRR, MTR, MMP2, MKI67, LPL, LGALS3, LEP, JAK2, H3P10

Drugs

2'-O-(2-Methoxyethyl) phosphorothioate antisense oligonucleotide targeting the growth hormone receptor, Cyclo(-gamma-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonyl-L phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt, Lanreotide acetate ( SOMATULINE DEPOT, SOMATULINE LP ), Octreotide ( SANDOSTATINE ), Octreotide acetate (oral use), Octreotide chloride (lipid depot solution), Pasireotide ( SIGNIFOR, SIGNIFOR LAR ), Pegvisomant ( SOMAVERT ), Recombinant protein consisting of modified human growth hormone releasing hormone and the translocation and endopeptidase domains of botulinum toxin serotype D, Vapreotide

Interested in hearing about new therapies?

A number sign (#) is used with this entry because of evidence that growth hormone-secreting pituitary adenoma-2 (PITA2) is caused by mutation in the GPR101 gene (300393) on chromosome Xq26.

For a general phenotypic description and a discussion of genetic heterogeneity of pituitary adenoma, see 102200.

Molecular Genetics

Because GPR101 was implicated as the gene that drives the phenotype of X-linked early-onset gigantism related to a microduplication (see 300942), Trivellin et al. (2014) sequenced the GPR101 gene in 248 sporadic acromegaly patients. Trivellin et al. (2014) identified a recurrent GPR101 mutation (E308D; 300393.0001) in 11 of 248 sporadic acromegaly patients with somatic somatotropinoma. Three of these 11 appeared to carry a constitutive mutation that was detected in DNA from peripheral blood mononuclear cells (PBMCs). Trivellin et al. (2014) detected the mutation in the tumor DNA in the remaining 8 patients.

Kamenicky et al. (2015) screened their entire cohort of 263 patients with acromegaly or gigantism for germline mutations in GPR101 and found only 3 patients with the E308D mutation, including 2 previously reported by Trivellin et al. (2014); all 3 had adult-onset sporadic acromegaly. In another patient with sporadic acromegaly, Kamenicky et al. (2015) identified a novel germline D366E (300393.0002) mutation in the GPR101 gene. The mutation was not reported in the Exome Aggregation Consortium, 1000 Genomes Project, dbSNP, or Exome Variant Server databases.